Daiwa Securities Group Inc. - PUMA BIOTECHNOLOGY INC ownership

PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 146 filers reported holding PUMA BIOTECHNOLOGY INC in Q3 2019. The put-call ratio across all filers is 1.51 and the average weighting 0.1%.

Quarter-by-quarter ownership
Daiwa Securities Group Inc. ownership history of PUMA BIOTECHNOLOGY INC
ValueSharesWeighting
Q3 2022$0870.0%0.00%
Q2 2022$0870.0%0.00%
Q1 2022$0870.0%0.00%
Q4 2021$0
-100.0%
870.0%0.00%
Q3 2021$1,0000.0%870.0%0.00%
Q2 2021$1,0000.0%870.0%0.00%
Q1 2021$1,0000.0%870.0%0.00%
Q4 2020$1,000
-50.0%
87
-64.2%
0.00%
Q3 2020$2,0000.0%2430.0%0.00%
Q2 2020$2,0000.0%2430.0%0.00%
Q1 2020$2,0000.0%2430.0%0.00%
Q4 2019$2,000
-33.3%
2430.0%0.00%
Q3 2019$3,0000.0%2430.0%0.00%
Q2 2019$3,000
-66.7%
2430.0%0.00%
Q1 2019$9,000
+125.0%
243
+17.4%
0.00%
Q4 2018$4,000
-55.6%
2070.0%0.00%
Q3 2018$9,000
-25.0%
2070.0%0.00%
Q2 2018$12,000
-99.2%
207
-99.0%
0.00%
-100.0%
Q1 2018$1,476,000
-24.4%
21,694
+9.9%
0.01%
-14.3%
Q4 2017$1,952,00019,7440.01%
Other shareholders
PUMA BIOTECHNOLOGY INC shareholders Q3 2019
NameSharesValueWeighting ↓
HARVARD MANAGEMENT CO INC 600,000$45,216,0003.56%
Avalon Global Asset Management LLC 32,900$2,479,0001.79%
CORNERSTONE CAPITAL MANAGEMENT LLC 495,145$37,314,0001.58%
BB BIOTECH AG 521,991$39,337,0001.25%
WEATHERBIE CAPITAL, LLC 137,041$10,327,0001.20%
ADAGE CAPITAL PARTNERS GP, L.L.C. 5,686,668$428,527,0001.19%
TOBAM 318,384$23,994,0000.94%
Orbimed Advisors 1,195,500$90,093,0000.91%
Capital International Sarl 109,405$8,245,0000.74%
CAPITAL INTERNATIONAL LTD /CA/ 145,697$10,980,0000.73%
View complete list of PUMA BIOTECHNOLOGY INC shareholders